Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018, German Cancer Research Center
Credit: Bahr/DKFZ

Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) have now found that the role Myc plays is determined by a distant section of DNA that contains a cluster of gene enhancers. In certain blood cancer cells, this cluster has been altered, which affects Myc activity and thereby accelerates cancer growth and affects how the cancer responds to chemotherapy. This cluster of enhancers might therefore be a suitable target in the treatment of blood cancer. The findings are published in Nature in collaboration with the European Molecular Biology Laboratory (EMBL) and colleagues from Canada.

In every cell, specific proteins called transcription factors activate or suppress individual . "Thus, they facilitate the formation of all kinds of different cell types such as immune cells or cells, even though the genetic material is the same in all cells," said Andreas Trumpp from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM).

Myc is known as a classic protein. On the one hand, it functions as a transcription factor that is needed for normal blood formation from stem cells. On the other hand, it can lead to cancer if it is present at increased levels. However, the precise mechanisms of how Myc levels are controlled in each cell type have been largely unknown to date. Now, a team led by Trumpp, jointly with colleagues from EMBL, has discovered a gene region that regulates the activity of the Myc gene in the individual cell types of the blood.

The research team found that a cluster of called BENC is responsible for Myc's fine control. BENC is located in an area of the chromosome that is very distant from the controlled Myc gene. This cooperation works because the chromosome forms a kind of loop, thus establishing a direct vicinity of the enhancer and the Myc gene.

BENC has a complex structure: It comprises nine individual enhancer modules that are arranged like beads on a string. These modules, which again bind different transcription factors depending on the individual cell type, interact in different ways in the various cells of the blood system. Thanks to this finely tuned interaction, each cell produces exactly the level of Myc that it needs for its optimum development. BENC regulates the varying Myc levels that are needed, for example, in or in mature lymphocytes.

Having made this discovery, the investigators wanted to know whether BENC also plays a role in leukemia cells. In mice with leukemia, they were able to show that the cancer disappeared after silencing BENC. Carsten Bahr and Lisa von Paleske, who are the first authors of the study, have thus proven the fundamental importance of the enhancer cluster for this type of blood cancer. In cancer cells from some patients with acute myeloid leukemia (AML), the BENC cluster was multiplied and present in several copies. In other AML patients, only a single enhancer module was extremely active in AML stem cells. Both events lead to increased Myc levels in the cell and have an impact on cell division rates and, thereby, on response to chemotherapy. "Our results offer a possibility to better assess AML stem in the blood of leukemia patients," Trumpp explained. "As we already have therapy approaches to influence the activity of enhancers, BENC might even become a target for novel therapies against this type of blood cancer."

Explore further: The HLF gene protects blood stem cells by maintaining them in a resting state

More information: Carsten Bahr et al, A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies, Nature (2018). DOI: 10.1038/nature25193

Related Stories

The HLF gene protects blood stem cells by maintaining them in a resting state

January 17, 2018
The HLF gene is necessary for maintaining blood stem cells in a resting state, which is crucial for ensuring normal blood production. This has been shown by a new research study from Lund University in Sweden published in ...

Misregulated protein breakdown promotes leukemias and brain cancer

November 9, 2017
An enzyme that is responsible for the breakdown of specific amino acids in food plays a key role in the development of leukemias and brain cancer, according to scientists from the German Cancer Research Center (DKFZ) in Heidelberg. ...

The HLF-gene controls the generation of our long-term immune system

November 22, 2017
A research group at Lund University in Sweden has found that when the HLF (hepatic leukemia factor) gene –which is expressed in immature blood cells – does not shut down on time, we are unable to develop a functional ...

New insights into T-cell acute lymphoblastic leukaemia development

May 30, 2017
A research team from the National University of Singapore (NUS) led by Assistant Professor Takaomi Sanda, Principal Investigator from the Cancer Science Institute of Singapore and Department of Medicine at NUS Yong Loo Lin ...

ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression

August 2, 2017
ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression, according to a study published August 2, 2017 in the open-access journal PLOS ONE by Varun Vijay Prabhu from Oncoceutics, Inc., USA and ...

Recommended for you

Researchers identify a mechanism that fuels cancer cells' growth

November 14, 2018
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified sodium glucose transporter 2, or SGLT2, as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes ...

A new approach to detecting cancer earlier from blood tests: study

November 14, 2018
Cancer scientists led by principal investigator Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have combined "liquid biopsy", epigenetic alterations and machine learning to develop a blood test to detect and classify ...

New antibody breakthrough to lead the fight against cancer

November 14, 2018
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defence against the body's immune system.

Photoacoustic imaging may help doctors detect ovarian tumors earlier

November 14, 2018
Ovarian cancer claims the lives of more than 14,000 in the U.S. each year, ranking fifth among cancer deaths in women. A multidisciplinary team at Washington University in St. Louis has found an innovative way to use sound ...

Solving the mystery of NPM1 in acute myeloid leukemia

November 13, 2018
Although it has long been recognized that mutations of gene NPM1 play an important role in acute myeloid leukemia, no one has determined how the normal and the mutated forms of the protein NPM1 function.

Cognitive decline—radiation—brain tumor prevented by temporarily shutting down immune response

November 13, 2018
Treating brain tumors comes at a steep cost, especially for children. More than half of patients who endure radiation therapy for these tumors experience irreversible cognitive decline, a side-effect that has particularly ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.